Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events.

Faisal Fa'akMaryam BuniAdewunmi FalohunHuifang LuJuhee SongDaniel H JohnsonChrystia M ZobniwVan A TrinhMuhammad Osama AwiwiNourel Hoda TahonKhaled M ElsayesKaysia LudfordEmma J MontazariJulia ChernisMaya DimitrovaSabina SandigurskyJeffrey A SparksOsama Abu-ShawerOsama RahmaUma ThanarajasingamAshley M ZemanRafee TalukderNamrata SinghSarah H ChungPetros D GrivasMay DaherAla AbudayyehIman OsmanJeffrey S WeberJean H TayarMaria E Suarez-AlmazorNoha Abdel-WahabAdi Diab

Published in: Journal for immunotherapy of cancer (2023)

Targeting IL-6R could be an effective approach to treat several irAE types without hindering antitumor immunity. This study supports ongoing clinical trials evaluating the safety and efficacy of tocilizumab (anti-IL-6R antibody) in combination with ICIs (NCT04940299, NCT03999749).

Keyphrases

clinical trial
rheumatoid arthritis
cancer therapy
rheumatoid arthritis patients
drug delivery
open label
juvenile idiopathic arthritis
disease activity